SCM
ALDX icon

Stonepine Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Stonepine Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200,000
Closed -$800K – 29
2021
Q4 		$800K Buy
+200,000
New +$1.53M 0.37% 23
2018
Q4 		– Sell
-145,000
Closed -$2M – 23
2018
Q3 		$2M Buy
+145,000
New +$1.18M 1.17% 23

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Stonepine Capital Management's ALDX Position: Q1 2022 in Review

Stonepine Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2022, closing a stake of 200,000 shares — an estimated $800K sold.

Stonepine Capital Management first reported a position in ALDX in Q3 2018 and held it in 2 quarters. The position peaked at $2M in Q3 2018. 111 funds tracked by Wall St. Rank hold ALDX as of Q1 2022.

  • Stonepine Capital Management reported no remaining Aldeyra Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Stonepine Capital Management sold 200,000 Aldeyra Therapeutics shares in Q1 2022, an estimated $800K.
  • Stonepine Capital Management first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 2 quarters.
  • Stonepine Capital Management's Aldeyra Therapeutics position peaked at $2M in Q3 2018.
  • 111 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2022.

Based on Stonepine Capital Management's 13F filing for Q1 2022, filed 16 May 2022.